Introduction {#Sec1}
============

Neurodevelopmental disorders (ND), which mostly involve developmental delay (DD), intellectual disability (ID) and/or autism spectrum disorders (ASD), affect around 3--4% of the world's population^[@CR1],[@CR2]^. Such disorders, when isolated, are termed non-syndromic; when associated with the presence of dysmorphisms or apparent congenital anomalies (CA), are termed syndromic^[@CR3]^.

Individuals affected with ND usually present reduced adaptive skills and/or limited intellectual ability and face major challenges throughout their life, often including motor difficulties, CA and problems with social interaction. These are relevant characteristics which affect not only the patient, but also impact the daily life of family members due to their special care and dedication needs^[@CR3],[@CR4]^.

Adequate diagnosis is necessary for the clinical follow-up of individuals with ND and to provide appropriate genetic counseling to the family, preventing the risk of recurrence. Hundreds of genes and many different chromosomal changes are associated with ND and, apart from the well-known and easy identifiable syndromes, the diagnosis of each affected individual remains a clinical challenge.

Due to their high phenotypic and genetic heterogeneity, studies and diagnostics of ND are intricate. Additionally both, genetic and environmental factors, isolated or together, play an important role in their pathogenesis^[@CR5],[@CR6]^. Currently, molecular karyotyping by chromosomal microarrays (CMA) has been clinically recommended as the first-tier cytogenetic diagnostic test of choice in the investigation of patients with idiopathic ND, such as developmental delay, intellectual disability, autism spectrum disorder and multiple congenital anomalies^[@CR7]^.

After the publication of the first comprehensive map of copy number variation in the human genome^[@CR8]^, that lead the authors to suggest that CNV assessment should become standard in the design of all studies of the genetic basis of phenotypic variation, including disease susceptibility, a growing number of publications have reported the diagnostic yield of CMA in cohorts of patients with ND, with a worldwide average rate of 15% to 20% in recent years^[@CR5],[@CR9]--[@CR18]^, (Table [1](#Tab1){ref-type="table"}).Table 1Some recent studies that used chromosomal microarrays for diagnostic testing in cohorts of affected individuals and their diagnostic rates.Study/YearCohortCMA PlatformsSample NoDetection Rate of Pathogenic CNVsBruno *et al*.^[@CR53]^Australia patents with ID and CAAFFYMETRIX 250K microarrays11715%Kashevarova *et al*.^[@CR11]^Russian patients with IDAGILENT 44K e 60K.7928%Bartnik *et al*.^[@CR13]^Polish patients with neurodevelopmental disorderV8 OLIGO 180k (customized)25616%Preiksaitiene *et al*.^[@CR15]^Lithuanian patients with neurodevelopmental disorderAGILENT 105k and 400k20114%Roselló *et al*.^[@CR5]^Spanish children with neurodevelopmental disorderAGILENT 44K24630%Coutton *et al*.^[@CR14]^French children with moderate ID4 × 180K OLIGONUCLEOTIDE ARRAY (AGILENT TECHNOLOGIES)6621%Lay-Son *et al*.^[@CR16]^Chilean patients with neurodevelopmental disorderCYTOSCAN HD, AFFYMETRIX4025%Pfundt *et al*.^[@CR9]^North American patients with disorder neurodevelopmentCYTOSCAN DX, AFFYMETRIX (Platform similar to CYTOSCAN HD)96014% (first line test)\*Quintela *et al*.^[@CR26]^Galician patients with neurodevelopmental disorder (Spain)CYTOGENETICS WHOLE-GENOME 2.7 M (n = 126) and CYTOSCAN HD (n = 447)57311,2% to 13,6%Wu *et al*.^[@CR12]^Children with congenital heart disease (Chinese population)AFFYMETRIX CYTOSCAN HD10428%Borlot *et al*.^[@CR24]^Patients with unexplained childhood-onset epilepsy and intellectual disability (Toronto)4 × 180K OLIGONUCLEOTIDE ARRAY (AGILENT TECHNOLOGIES)13416%HEIDE *et al*.^[@CR27]^Patients with both corpus callosum abnormality and intellectual disability (French)370 CNV-QUAD (n = 7), CYTOSNP-12 (n = 121) our HUMANOMNIEXPRESS-24 (n = 21) (ILLUMINA)14913%Di Gregorio *et al*.^[@CR54]^Patients diagnosed with DD/ID in Turin, ItalyAGILENT 60K101511%Sansović *et al*.^[@CR55]^Patients with DD/ID with or without dysmorphism, ASD, and/or CA (Croatia)AGILENT SUREPRINT G3 UNRESTRICTED CGH ISCA V233722%Kessi *et al*.^[@CR56]^Patients with ID/DD and epilepsy (Chinese population)AFFYMETRIX + SNP Microarray And ILLUMINA HUMANCYTOSNP-1210025%^\*^CMA used as a first line test (no screening with classical cytogenetics). CYTOSCAN HD platform validation study at FDA. DD = developmental delay; ID = intellectual disability; CA = congenital anomalies; ASD = autism spectrum disorder.

Although the CMA test is considered the gold standard in the diagnostics of ND, in Latin America classic karyotyping is still the predominant genetic test in clinical practice, and in Brazil there are only a few publications of CMA in cohorts of ND patients. Pereira and coworkers^[@CR7]^ analyzed 15 patients with ND attended by the Laboratory of Human Cytogenetics and Molecular Genetics of the PUC (Pontifical Catholic University) of Goiás between 2010 and 2012, with a diagnostic rate of 22% using the CYTOSCAN HD platform. In Espírito Santo, Pratte-Santos and coworkers^[@CR19]^ investigated 39 individuals with ND and a normal karyotype, with the 4 × 180K CMA platform from Agilent, reporting a 15% rate of pathogenic CNVs. In the Northeast of Brazil, Vianna and coworkers^[@CR20]^, using a 60K microarray platform (Agilent) in 200 patients with ND, found pathogenic CNVs in 33 of them, a diagnostic rate of 16.5%.

Our study analyzed a cohort of 420 patients from the south of Brazil, that underwent microarray testing from 2013--2016 for diagnostic purpose.

Results {#Sec2}
=======

Of the 420 participating patients, 260 (62%) were male and 160 (38%) female, from 0 to 49 years of age, with a mean age of 9.5 years (SD = 9.73, Mo = 4). For 139 patients previous karyotyping was reported, 122 with normal result and 17 with abnormal results for which CMA was requested to define the sequences involved.

For most patients' previous genetic assessments are unclear.

From the 420 microarrays, a total of 2,468 CNVs which fulfilled the filtering criteria were selected; 1,462 duplications and 1,007 deletions which were interpreted and classified into benign CNVs, pathogenic CNVs and variants of uncertain clinical significance (VOUS).

In 18% patients (75/420) we identified a total of 96 rare CNVs which were interpreted as pathogenic (Table [2](#Tab2){ref-type="table"}). Of these 75 patients, 15 had more than one pathogenic CNV, 9 of them had 2 pathogenic CNVs (\#33, \#47, \#61, \#127, \#251, \#332, \#372 and \#407) and 6 had 3 pathogenic CNVs (\#151, \#188, \#196, \#219, \#270 and \#392). Three cases (\#81, \#255 and \#331), along with a pathogenic CNV, also presented VOUS. Of the 96 pathogenic CNVs 58 were deletions, leaving only a single copy of the sequence involved. The remaining 38 were duplications that usually result in a total of three copies of the sequence involved, however in two brothers (cases \#24 and \#25) the duplication of a relevant region of chromosome X resulted in two copies (in which the main reason of pathogenicity is the fact that none of the duplicated copies undergoes X-inactivation, as usual in females) and in three patients (cases \#306, \#422 and \#443) the CNV found was in a four-copy state, of which case \#422 had a previous abnormal karyotype result (Table [2](#Tab2){ref-type="table"}). The pathogenic CNVs were found in all chromosomes, except in chromosome 11. Figure [1](#Fig1){ref-type="fig"} illustrates the frequency and number of pathogenic CNVs found per chromosome.Table 2Pathogenic CNVs found in the cohort.CaseCNVMicroarray NomenclatureSize (Kbp)N° of GenesSome of the Relevant GenesPhenotypeGender/other infoInheritanceKaryotypeSyndrome\#9Delarr\[hg19\] 13q33.1q34(104,782,510--112,352,804)x17.57026COL4A2, DAOA-DD, LDO, FD, low weight, microcephaly and mot difM/−ND---\#15Delarr\[hg19\] 16p11.2(28,689,085--29,043,863)x135518SH2B1DD, AutM/Affected brother (\#16)NDdistal 16p11.2 deletion syndrome\#16Delarr\[hg19\] 16p11.2(28,689,085--29,388,495)x136218SH2B1DD, AutM/Affected brother (\#15)NDdistal 16p11.2 deletion syndrome\#18Delarr\[hg19\] 6q15-q21(93,082,925--110,504,681)x117.42266SIM1, SEC. 63DD, CA, FD, SLDM/Affected brother (\#19 in Table [2](#Tab2){ref-type="table"})ND---\#24Duparr\[hg19\] Xq27.3q28(146,425,635--151,604,987)x25.17940FMR1, AFF2DD, SLD, FD and obesityM/Affected brother (\#25)ND---\#25Duparr\[hg19\] Xq27.3q28(146,418,810--151,604,987)x25.18640FMR1, AFF2DD, SLD, FD and obesityM/Affected brother (\#24)ND---\#26Delarr\[hg19\] 22q11.21(18,648,855--21,269,224)x12.62058TBX1DIL, mot dif, hyperactivityF/−NDDi George syndrome\#33Delarr\[hg19\] 18p11.32p11.23(136,227--8,348,006)x18.21243TGIFSID, mot dif and FD and hypotoniaF/\*2PvND18p deletion syndrome\#33Delarr\[hg19\] 18q22.2q23(67,357,305--78,013,728)x110.65643RTTN, CTDP1SID, mot dif and FD and hypotoniaF/\*2PvND---\#44Delarr\[hg19\] 22q13.2q13.33(43,600,479--51,197,766)x17.59795UPK3A, FBLN1, SHANK3DIM, Mot Dif, FD and CAF/−ND46, XX, del(22)(q13)Phelan-McDermid Syndrome\#47Delarr\[hg19\] Xp22.33(372,029--578,764)x12070SHOXShort statureF/\*2PvNDLeri-Weill dyschondrosthosis syndrome\#47Delarr\[hg19\] Xp22.33(679,520-950,907)x12710SHOXShort statureF/\*2PvNDLeri-Weill dyschondrosthosis syndrome\#52Delarr\[hg19\] 22q13.33(50,788,193--51,115,526)x132718SHANK3SID, Aut, mot dif, FD, CA and epilepsy.M/NDPhelan-McDermid syndrome\#56Delarr\[hg19\] 8p21.1p11.21(28,393,484--41,026,001)x112.63269NRG1, FGFR1, ANK1DIL, FDM/−NDXY, 46, del(8)(p21-p11)8p intersticial deletion including p12 syndrome\#61Delarr\[hg19\] 13q34(114,141,294--115,107,733)x196615TFD1, GRK1, RASA3, GAS6, CHAMP1DIL, hyperactivityM/\*2Pv/4 affected siblingsNDDistal 13q deletion\#61Duparr\[hg19\] 8p23.3p23.1(158,048--8,142,435)x37.98464ARHGEF10, MCPH1DIL, hyperactivityM/\*2Pv/4 affected siblingsNDDistal trisomy 8p\#66Duparr\[hg19\] 15q25.1q26.3(80,304,866--102,429,040)x322.124175AKAP13, CPEB1, NTRK3, WDR73SID, Aut, convulsions, SLD, hyperactivity, one kidney and FDM/−ND---\#69Delarr\[hg19\] 16p12.2p11.2(21,405,327--29,388,495)x17.98382SH2B1DIL, Aut, SLD, hyperactivity and FDM/−ND---\#70Duparr\[hg19\] 7q11.23(72,732,834--74,155,067)x31.42227WBSCR27, WBSCR28DIM, Aut and hyperactivityM/−ND---\#76Duparr\[hg19\] 7q11.23(72,556,215--74,245,599)x31.68934WBSCR27, WBSCR28DIL, AutM/−NDWilliams-Beuren region duplication syndrome\#77Delarr\[hg19\] 15q13.2q13.3(31,073,735--32,446,830)x11.3739CHNA7DIL, Aut and hyperactivityM/−ND---\#81Delarr\[hg19\] 17q21.31(43,574,907--44,212,415)x163711KANSL1SLD, convulsions and FDM/\*VOUSND---\#85Duparr\[hg19\] 7q31.32q33(122,739,692--136,150,625)x31.341101WASLDIL, mot dif, hyperactivity, FD and CAF/−ND---\#91Duparr\[hg19\] 16p13.3p13.12(85,880--14,524,038)x314.438262CREBBPSID, AutM/−ND16p13.3 microduplication syndrome\#93Delarr\[hg19\] 3p14.1p13(68,988,297--70,938,968)x11.9518MITF, TMF1Deafness, ophthalmopathy and ADHDF/−NDWaardenburg syndrome type II\#95Delarr\[hg19\] 22q11.21(18,648,855-21,058,888)x12.41055TBX1DIL, mot dif and hyperactivityF/NDDi George syndrome\#102Delarr\[hg19\] Xp22.31(6,449,752--8,135,644)x11.7157STSDD and FDF/−---\#105Delarr\[hg19\] 1p36.33p36.32(1,073,574-2,458,606)x11.38554GABRD, SKIDIM and FDM/−---\#107Duparr\[hg19\] 7p21--p22.3 (43,376--9,454,786)x39.411145RNF216MID, convulsions and FDM/---\#113Delarr\[hg19\] 16p13.3(85,880--2,145,951)x12.060108TSC2, SOX8DD, FD and tuberous sclerosisF/affected twin sister (\#115)NDATR-16 syndrome (\#141750) (thalassemia/mental retardation syndrome)\#115Delarr\[hg19\] 16p13.3(85,880--2,146,448)x12.060108TSC2, SOX8DD, FD and tuberous sclerosisF/affected twin sister (\#113)NDATR-16 syndrome -- (\#141750) (thalassemia/mental retardation syndrome)\#116Duparr\[hg19\] Xq26.3q28(135,224,845--155,233,098)x220.008212GPR101, fmr1, fmr2, MECP2, RAB39B, FLNA, GDI1Low weight, abnormal growth, prematurity, CA, DD, FD and microcephalyM/−ND46, XY, add(22q)Xq26.3, Xq27.3-q28 and Xq28 duplication syndromes\#127Duparr\[hg19\] 10q25.1q26.3(108,553,165--135,427,143)x326.873182101 OMIMsLow weight, CA, DD, ID, epilepsy and FDF/\*2Pv46, XX, der(18)t(10; 18) (q25.2; q22,2) mat46, XX, add(18)(q23)distal trisomy 10q syndrome\#127Delarr\[hg19\] 18q22.3q23(69,055,745--78,014,123)x18.9583662 OMIMsLow weight, CA, DD, ID, epilepsy and FDF/\*2Pv46, XX, der(18)t(10; 18) (q25.2; q22,2) mat.46, XX, add(18)(q23)18q deletion syndrome\#130Delarr\[hg19\] 15q11.2(22,770,421--23,209,654)x17326NIPA1, NIPA2, CYF1P1, TUBGCP5Short stature, DD, ADHD and FDM/−ND15q11.2 BP1--BP2 microdeletion syndrome (OMIM 615656)\#148Delarr\[hg19\] Xp22.3q28(1--247,249,719)x3 ou arr(X)x3155.270------DD, Aut and schizophreniaF/−NDTriple X syndrome\#149Delarr\[hg19\] 5p15.31p14.3(6,801,589--18,992,827)x112.19140---Hypotonia, DD, SLD, behavioral disorder and FDF/Sister of \#44546, XY, t(1; 2)(q44;\~p23-pter); t(5; 7)(p14.3-p15.31; p22) pat.Cri du-Chat syndrome\#151Delarr\[hg19\] 18p11.32p11.31(136,226--4,409,550)x14.27326TGIF1, SMCHD1Short stature, FD, IUGR and DDM/\*3PvND---\#151Duparr\[hg19\] 7p22.3p21.3(43,376--9,454,786)x39.4119250 OMIMsShort stature, FD, IUGR and DDM/\*3PvND---\#151Duparr\[hg19\] Xq28(151,356,116--155,233,731)x23.877106MECP2, L1CAMShort stature, FD, IUGR and DDM/\*3PvNDXq28 duplication syndrome\#160Delarr\[hg19\] 2q31.1-q31.2(174,065,715--190,659,870)x116.582160HOXD, CHN1Short stature, DD, ID, SLD, epilepsy and FDF/−ND2q31.1 microdeletion syndrome\#169Delarr\[hg19\] 18p11.32p11.21(136,226--15,181,666)x115.04586TGIF1, SMCHD1ID, FD and short statureF/−De Novopartial 18p deletion syndrome\#171Duparr\[hg19\] 7q31.32q33(122,739,692--136,150,625)x313.411101LEPDD and IDF/−NDpartial trisomy 7q31.32q33\#181Delarr\[hg19\] 22q13.31q13.33(46,168,628--51,115,526)x14.94766SHANK3Slender build, hypotonia, convulsions, DD and FDF/−NDPhelan-McDermid syndrome\#184Delarr\[hg19\] 15q11.2q13.1(22,770,421--28,823,722)x16.053121UBE3A, SNRPNDD, ID, epilepsy, Aut and ADHDM/−NDAngelman/Prader - Willi syndrome\#188Duparr\[hg19\] 19p13.3(1,712,849--6,074,347)x34.361131SEMA6B, MAP2K2DD, FD and microcephalyM/\*3PvNDpartial trisomy 19p13\#188Duparr\[hg19\] 19p13.3(260,911--1,434,508)x31.17452---DD, FD and microcephalyM/\*3PvNDpartial trisomy 19p13\#188Delarr\[hg19\] 21q22.3(46,597,460--48,097,372)x11.45024---DD, FD and MicrocephalyM/\*3PvND---\#196Duparr\[hg19\] 18q21.2q22.1(49,094,563--66,586,144)x317.49268PIGNShort stature, CAs, DD, SLD and FDF/\*3PvND46, XX, 5p+partial trisomy 18q\#196Duparr\[hg19\] 18q22.1q23(66,593,317--78,014,123)x311.42141PIGNShort stature, CAs, DD, SLD and FDF/\*3PvND46, XX, 5p+Distal trisomy 18q\#196Delarr\[hg19\] 5p15.33p15.2(113,576--12,747,875)x112.63472CTNND2, TERTShort stature, CAs, DD, SLD and FDF/\*3PvND46, XX, 5p+Cri du-Chat syndrome\#216Delarr\[hg19\] 17q21.31(43,703,801--44,212,416)x15089KANSL1Low weight, short stature, fanconi anemia, DD, SLD and FDF/−NDKoolen de Vries syndrome\#219Duparr\[hg19\] 8p11.22p11.21(39,388,765--42,335,424)x32.9462218 OMIMsShort stature, prematurity, IUGR, DD and FDF/\*3PvND46, XX, add(8)(p23.1)8p inverted duplication/deletion \[invdupdel(8p)\] syndrome\#219Duparr\[hg19\] 8p23.1p11.22(11,935,023--39,246,760)x327.311191119 OMIIMsShort stature, prematurity, IUGR, DD and FDF/\*3PvND46, XX, add(8)(p23.1)8p inverted duplication/deletion \[invdupdel(8p)\] syndrome\#219Delarr\[hg19\] 8p23.3p23.1(158,048--6,940,661)x16.7823115 OMIMsShort stature, prematurity, IUGR, DD and FDF/\*3PvND46, XX, add(8)(p23.1)8p inverted duplication/deletion \[invdupdel(8p)\] syndrome\#235Duparr\[hg19\] 17p11.2(16,591,260--20,473,937)x33.88268RAISlender build, DD, SLD, DIM, Aut and FDF/−NDPotocki-Lupski syndrome\#236Duparr\[hg19\] 17q23.3q24.2(62,339,243--65,959,327)x33.62031BPTF, PSMD12Slender build, DD, behavioral disorder, FD, Microcephaly and CardiomyopathyF/−ND---\#237Delarr\[hg19\] 13q21.32q32.1(65,840,171--95,798,028)x129.95874---Not reportedF/−NDpartial 13q monosomy syndrome\#238Delarr\[hg19\] 7p14.1p12.3(41,339,411--47,849,443)x16.51059GLI3CAs, DD, SLD, ID and FDF/−NDGreig syndrome\#249Delarr\[hg19\] 10q26.11q26.3(121,477,949--135,426,386)x113.948105---DD, ID, FD and microcephalyF/−ND10q26 deletion syndrome\#251Duparr\[hg19\] 19p13.3(260,911--2,328,485)x32.0689061 OMIM genesObesity, DD, ID, FD and ectodermal dysplasiaM/\*2PvNDpartial trisomy 19p13 syndrome\#251Delarr\[hg19\] 20q13.33(62,288,778--62,913,645)x16253216 OMIM genesObesity, DD, ID, FD and ectodermal dysplasiaM/\*2PvND---\#255Duparr\[hg19\] 22q11.21q11.23(18,493,187--24,313,652)x35.820125TBX1DD, Aut and FDM/\*VOUSND22q11.21 duplication syndrome\#263Delarr\[hg19\] 9p24.2p22.2(4,339,192-18,272,756)x113.9344532 OMIMsHypotonia, CAs, DD and FDM/−ND47, XY + mar9p deletion syndrome\#264Duparr\[hg19\] 1q21.1q21.2(146,496,425--147,819,815)x31.32316PRKAB2, FMO, CHD1L, GJA5, GJA8, GPR89BHyperactivity, behavioral disorder, SLD, ASD, LDM/−ND1q21.1 duplication syndrome\#270Delarr\[hg19\] 15q11.2(22,770,421--23,282,799)x15128NIPA1, NIPA2, CYF1P1, TUBGCP5Convulsions, CAs, DD, epilepsy, hearing deficit, FD and hirsutismM/\*3PvND15q11.2 BP1--BP2 microdeletion syndrome (OMIM 615656)\#270Delarr\[hg19\] 18q22.1q23(65,997,926--78,014,123)x112.01642RTTN, MBPP, TSHZ1Convulsions, CAs, DD, epilepsy, hearing deficit, FD and hirsutismM/\*3PvND---\#270Duparr\[hg19\] 3q26.32q29(178,907,147--197,851,986)x318.945180112 OMIMsConvulsions, CAs, DD, epilepsy, hearing deficit, FD and hirsutismM/\*3PvND---\#296Delarr\[hg19\] 16p11.2(29,580,020--30,176,508)x159628ALDOAObesity, convulsions, DD, SLD, LDO., ID, epilepsy and hypoglycemiaM/−ND16p11.2 deletion syndrome\#305Duparr\[hg19\] Xq27.3q28(142,412,280--155,233,098)x212.821167FMR1-AS1, FMR1, AFF2, MECP2Obesity, CAs, DD, ID, FD and cutis marmorataM/−ND46, XY, add(X)(p22)Xq27.3-q28 and Xq28 duplication syndrome\#306Duparr\[hg19\] 15q11.2q13.1(23,286,571--28,946,433)x45.660116CYF1P1, PWRN1, PWRN2, SNRPM, UBE3ADDM/−ND15q11-q13 duplication syndrome\#312Delarr\[hg19\] 22q11.21(18,916,842--21,798,907)x12.88270TBX1CAs, SLD, LDO. and FDM/−NDDi George syndrome\#331Delarr\[hg19\] 4p16.3(68,345--964,416)x189618LETM1, WHSC1DD, Epilepsy and FDM/\*2Pv/\*VOUSNDWolf-Hirschhorn syndrome\#331Delarr\[hg19\] 4p16.3(970,878--4,015,580)x13.04550NSG1DD, Epilepsy and FDM/\*2Pv/\*VOUSND---\#332Duparr\[hg19\] 3q29(192,443,188--197,851,986)x35.4097035 OMINsDD, ID and FDF/\*2PvND3q29 Microduplication syndrome\#332Delarr\[hg19\] 7q34q36.3(143,069,244--159,119,707)x116.05014267 OMIMsDD, ID and FDF/\*2PvND7q34-36 deletion syndrome\#339Delarr\[hg19\] 12p13.2p13.1(10,922,516--12,937,320)x12.01540LRP6Slender build, FD, and alopeciaF/−ND46, XX, Inv (12)(p13q24.1)---\#343Delarr\[hg19\] 1p36.33p36.31(849,466--5,830,248)x14.98194GABRD, PRKC2, SKI,DD, SLD, ID, CAs and hypothyroidismF/−ND1p36 deletion syndrome\#345Delarr\[hg19\] 14q32.2q32.31(100,095,248--102,755,064)x12.660117PEGS (DLK1 and RTL1), MEGS (MEG3 and MEG8)Low weight, short stature, prematurity, IUGR, ataxia, scoliosis, DD, SLD, SID, Aut, FD and early pubertyF/−NDTemple syndrome\#366Delarr\[hg19\] 6q25.1q26(150,944,729--164,003,180)x113.05871ARID1BLow weight, short stature, CAs, DD, FD and ventricular septal defectF/−ND6q25.1 deletion syndrome\#372Duparr\[hg19\] 4p16.3p16.1(68,345--9,509,606)x39.44114872 OMIMsHypotonia, DD, SLD, LDO., DIL and behavioral disorderM/\*2PvND---\#372Delarr\[hg19\] 8p23.3p23.1(158,048--6,938,050)x16.78046MCPH1Hypotonia, DD, SLD, LDO, DIL and behavioral disorderM/\*2PvND---\#377Duparr\[hg19\] 22q11.21(18,648,855--21,461,017)x32.81269TBX1Convulsions, ID, DD, SLD, ADHD and FDM/−ND22q11.21 duplication syndrome\#385Delarr\[hg19\] 21q22.12q22.2(35,834,713--39,831,660)x13.99732DYRK1AConvulsions, ID, DD, SLD, Aut, cardiomyopathy, abnormal external genitalia and thrombocytopeniaM/−ND21q22.12 microdeletion syndrome\#392Duparr\[hg19\] 21q11.2q22.3(15,006,457--44,968,648)x329.962224---Not reportedM/\*3PvND46, XY, r(21)(p21q22.3)\[?\]/46, XY, idic(21)(p13)\[?\]trisomy of chromosome 21\#392Duparr\[hg19\] 21q22.3(44,974,017--45,685,800)x371112---Not reportedM/\*3PvND46, XY, r(21)(p21q22.3)\[?\]/46, XY, idic(21)(p13)\[?\]---\#392Delarr\[hg19\] 21q22.3(45,685,800--48,097,372)x12.41158---Not reportedM/\*3PvND46, XY, r(21)(p21q22.3)\[?\]/46, XY, idic(21)(p13)\[?\]Terminal 21q del\#399Duparr\[hg19\] 17p11.2(16,591,260--20,462,723)x33.87169RAIShort stature, DD, FD and macrocephalyF/−NDPotocki-Lupski syndrome\#407Delarr\[hg19\] 21q22.3(45,434,816--48,093,361)x12.65963---Low weight, abnormal growth, convulsions, neuropathies, DD, FD and congenital cardiopathyF/\*2PvND---\#407Duparr\[hg19\] 3q26.1q29(166,855,496--197,851,444)x330.996228SHOX2Low weight, abnormal growth, convulsions, neuropathies, DD, FD and congenital cardiopathyF/\*2PvND46, XX, add(21)(q22.3)Distal trisomy 3q\#409Delarr\[hg19\] 22q11.21(18,916,842--20,716,903)x11.80046PRODH, TBX1, DGCR6LCAs, ligament laxity, DD and FDM/−NDDi George syndrome\#416Delarr\[hg19\] 18q21.32q23(58,921,746--78,013,728)x119.09275PIGNObesity, CAs, DD, ID, deafness, Aut, FD and thrombocytopeniaM/−ND18 q21.32-qter deletion syndrome\#422Duparr\[hg19\] 18p11.32p11.21(136,227--15,099,116)x414.9638846 OMIMsCAs, DD, FD, macrocephaly and renal cystsM/karyotype 47, XY +mar(30)ND47, XY + martetrasomy 18p11.21-p11.32\#433Duparr\[hg19\] 7q31.32q33(122,736,512--136,162,906)x313.426101LEPIDM/−NDpartial trisomy 7q31.32q33\#443Duparr\[hg19\] 22q12.3q13.1(35,888,588--38,692,765)x42.8045945 OMIMsLow weight, short stature, DD, SLD, Aut, behavioral disorder, FD and mongolian stainsM/−ND---\#445Duparr\[hg19\] 5p14.3--p15.31 (6,801,589--18,992,827)x312.131------Not reportedBrother of \#14946, XY, t(1; 2)(q44;\~p23-pter); t(5; 7)(p14.3-p15.31; p22) pat.partial trisomy 5p14.3-p15.31Pathogenic CNVs found by CMA in the cohort, with the number of genes present in the region, listing the most relevant genes and phenotypes for each individual. Du p = Duplication, Del = Deletion, CA = congenital anomalies, DD = developmental delay, MID = mild intellectual disability, SID = severe intellectual disability, Aut = autism, Mot Dif = motor difficulties, FD = facial dysmorphisms, SLD = speech and/or language delay or impairment, IUGR = intrauterine growth restriction, ADHD = Attention-deficit/hyperactivity disorder, LDO = learning difficulty only, LD = Learning disability, ND = not determined. F = Female, M = Male. \*VOUS = Patients with VOUS (CNV). \*2**Pv** = Patients with 2 pathogenic CNVs. \*3**Pv** = Patients with 3 pathogenic CNVs.Figure 1Pathogenic CNVs per chromosome.

Variants of uncertain significance (VOUS), which also are rare CNVs, were the main findings in 12% (49/420) of the patients, summing up a total 56 CNVs, 17 deletions and 39 duplications, (Table [3](#Tab3){ref-type="table"}). These variants were found on most chromosomes except for 21, 22 and Y, and contained from 1 to 48 genes (SD = 10:19, Mo = 4), of which from 1 to 28 (SD = 5.06 Mo = 2) are genes cited in the OMIM database (OMIM genes). Figure [2](#Fig2){ref-type="fig"} illustrates the frequency and amount of VOUS per chromosome.Table 3VOUS found in the cohort.CaseTypeMicroarray NomenclatureSize (Kbp)N° of GenesN° of Genes in OMIMImportant GenesPhenotypeGender/Notes\#1Duparr\[hg19\] 2p24.1(23,982,758-24,813,485)x3831187ATAD2B, UBXN2AMID, overweightF\#5Duparr\[hg19\] 6q15(89,917,335-90,485,874)x356874GABRR1, GABRR2MID, Mot Dif and hyperactivityM\#6Duparr\[hg19\] 2q37.2q37.3(236,733,535-237,355,774)x362242AGAP1, GBX2DD, convulsions and FDF\#7Duparr\[hg19\] 1q44(246,324,898-246,688,599)x336321SMYD3Aut, Mot Dif, convulsions and FDM\#13Delarr\[hg19\] 11q14.1(84,050,388-84,415,990)x136511DLG2Aut, LDO, Mot Dif, FD and SLDM\#19Duparr\[hg19\] 8q21.13(82,061,218-84,515,685)x42.454106IMPA1DD, FD, gastroschisis bladder exstrophy, hydronephrosis and Abnormal growthM/Affected brother (\#18)\#21Delarr\[hg19\] 2q13(110,504,318-111,365,996)x1861163NPHP1IDM\#32Duparr\[hg19\] 20q13.33(61,854,236-62,054,955)x320095KCNQ2, CHRNA1Convulsions, low weight, prematurity, FD,microcephaly and tracheoesophageal fistulaM\#40Delarr\[hg19\] 14q24.2(73,590,938-73,776,190)x118542PSEN1, NUMBP1Aut and SLDM\#43Delarr\[hg19\] 16q23.2(80,260,131-80,701,060)x144021DYNLRB2, CDYL2MID, Aut, Mot Dif, SLD, hyperactivity and FDM\#50Delarr\[hg19\] 13q12.12(60,425,635-60,688,042)x1262252SGCG, SACSMIDF\#58Duparr\[hg19\] 11q22.3(102,946,063-103,827,049)x388042DYNC2H1DD, LDO, Mot Dif and FDM\#64Duparr\[hg19\] 9q34.3(139,381,821-140,086,032)x37044828NOTCH1DD, SLD, ID and FDM\#81Duparr\[hg19\] 16p13.3(549,826-1,449,862)x39004526CACNA1HSLD, convulsions and FDM/\*Pv\#82Duparr\[hg19\] 4q35.2(188,106,543-189,797,261)x31.69151ZFP42DD and SLDM\#86Delarr\[hg19\] 13q21.2(60,425,635-60,688,042)x126221DIAPH3DD and LDOF\#89Duparr\[hg19\] 9p24.3(319,876-517,446)x319822DOCK8, KANK1Aut, SLD, mot dif and FDF\#109Duparr\[hg19\] 4q31.1(139,758,054-139,988,340)x323021CCRN4LDD and FDM\#112Duparr\[hg19\] 9p13.3(34,211,157-34,395,294)x318453UBAP1, NUDT2SID, Aut, convulsions, SLD, mot dif and FDM\#117Duparr\[hg19\] 19q13.33(48,206,212-48,431,081)x3224257CORD2Short stature, abnormal brain structure, CAs,DD, FD, hirsutism and anemiaF/−\#136Duparr\[hg19\] 4q28.1q28.2(128,789,028-128,891,808)x310332PLK4Low weight, short stature, IUGR, FD, thin hair,and skin spots - no IDF/−\#138Duparr\[hg19\] 6p21.2(37,609,169-37,868,513)x326022MDGA1Prematurity, DD, polydactyly, aggression,FD, difficulties of swallowing food, vomiting with fatty food,cutis marmorata,microcytic and hypochromic anemiaM/−\#144Delarr\[hg19\] 8q13.1q13.2(67,999,679-68,190,627)x119122CSPP1DD, SLD, ID and FDF/−\#178Duparr\[hg19\] 11q23.3(117,000,284-117,312,611)x3312107DSCAML1, CEP164, BACE1Slender build, DD,Aut, FD, macrocephalyM/−\#180Delarr\[hg19\] 16p13.3(6,243,228-6,835,898)x159311RBFOX1DD, hypothyroidismM/−\#215Delarr\[hg19\] 3q26.33(179,508,262-179,621,954)x111411PEX5LMotor Delay, DD, ID, Aut and ADHDM/−\#223Duparr\[hg19\] 15q24.1(72,838,805-73,581,757)x374384BBS4Short stature, IUGR, DD, MID and FDM/\*3 V\#223Duparr\[hg19\] 3p26.3(255,645-1,510,822)x31.25522CTN6, CHL1Short stature, IUGR, DD, MID and FDM/\*3 V\#223Duparr\[hg19\] 6q25.3(156,488,875-158,534,725)x32.04594ARID1B, SYNJ2Short stature, IUGR, DD, MID and FDM/\*3 V\#245Duparr\[hg19\] 14q12(26,490,666-27,520,832)x31.03021NOVA1Obesity, encephalopathy, CAs, DD and FDF/−\#248Delarr\[hg19\] 10q23.1(87,392,282-87,791,684)x139911GRID1Abnormal brain structure, DD,SLD, FD and microcephalyM/−\#255Delarr\[hg19\] 10q23.1(87,691,467-87,843,627)x115211GRID1DDM/\*Pv\#268Delarr\[hg19\] 2q13(110,504,318-111,365,996)x1861163NPH1ASDM/−\#276Duparr\[hg19\] Xq26.2(130,672,818-130,967,726)x329523KAL1DD, FD, cardiomyopathy, thyroid dysfunction and myopiaF/−\#278Duparr\[hg19\] 19q13.42(54,201,711-54,420,807)x3219399MIR, NLRP12Epilepsy, abnormal brain structureand IDF/−\#290Duparr\[hg19\] 2q13(110,496,601-110,983,418)x3487143NPHP1Genetic counselingM/−\#294Duparr\[hg19\] 2q13(110,498,141-110,980,295)x3482143NPHP1DD, ID, FD andCongenital cardiopathyF/−\#299Duparr\[hg19\] 17q11.2(28,952,286-29,150,025)x319841CRLF3DD, Aut andBehavioral disorderM/−\#309Delarr\[hg19\] 17p13.1(6,949,507-7,217,381)x12681615-Short stature, DD, ID, FD and microcephalyM/−\#311Duparr\[hg19\] 1p31.3(61,699,736-62,125,970)x342621NFIAObesity, CAs, DD,SLD and IDF/−\#319Duparr\[hg19\] 16p13.3(1,252,411-1,404,818)x3152985 OMIMsAnal imperforation, onfalocele and cloacal exstrophyF/−\#331Duparr\[hg19\] 4p16.3p16.2(4,025,257-4,618,896)x359473NSG1DD, epilepsy and FDM/\*Pv\#336Duparr\[hg19\] 1q25.3(183,589,206-183,827,325)x323833ARPC5, APOBEC4, RGL1DD and FDF/−\#342Delarr\[hg19\] 3p24.2(24,376,230-24,492,572)x111711THRBDD, Bilateral hearing impairment and FDF/−\#346Delarr\[hg19\] 7q31.1(111,485,313-111,922,531)x143722DOCK4Low weight, slender build,motor delay, DD, SLD, SID and Aut.M/−\#354Duparr\[hg19\] 9q33.1(118,409,943-119,207,073)x379743NOC2LConsanguineous parents, quadriparesis, DD, FD and ostium secundumM/−\#359Duparr\[hg19\] 5q14.1(80,019,759-80,535,750)x351663MSH3, RASGRF2, CKMT2Convulsions, LDO, MIDand behavioral disorderF/−\#360Delarr\[hg19\] 1p31.1(72,257,666-72,499,784)x124221NEGR1Convulsions, LDO, FMID and hearing lossF/−\#369Duparr\[hg19\] 12p11.22p11.21(30,175,955-31,570,927)x31.39493IPO8, CAPRIN2, DDX11Abnormal brain structureand DDM/−\#383Duparr\[hg19\] 10q11.23(51,250,417-51,755,110)x350574PARG, MSMBP, NCOA4, TIMM23Convulsions, DD, SLD, Aut., Behavioral disorder and gluten intoleranceM/−\#384Duparr\[hg19\] 10q21.1(59,984,568-60,285,875)x330155IPMK, CISD1, UBE2D1, TFAMMotor delay and chronic encephalopathyM/−\#384Delarr\[hg19\] 16p13.3(7,108,169-7,225,285)x111711RBFOX1Motor delay and chronic encephalopathyM/−\#384Duparr\[hg19\] 18q22.3(72,755,482-73,023,597)x326831TSHZ1Motor delay and chronic encephalopathyM/−\#397Duparr\[hg19\] 16p12.2(21,817,921-22,431,357)x361393UQCRC2, EEF2K, CDR2DD, Aut and FDM/−\#401Duparr\[hg19\] 2q11.1(95,733,867-96,279,208)x354583ZNF2, MRPS5, KCNIP3AutismF/−\#423Duparr\[hg19\] 12q21.31(80,559,698-80,918,615)x335822OTOGL, PTPRQCAs, ID and FDF/−\#444Delarr\[hg19\] 16p13.3(6,644,079-6,675,606)x13111RBFOX1ASDM/−Variants of unknown significance found in the cohort, with the number of genes present in the region, listing the most relevant genes and phenotypes for each individual. Dup = Duplication, Del = Deletion, CA = Congenital Anomalies, DD = Developmental Delay, ID = Unspecified intellectual disability, MID = Mild Intellectual Disability, MID = Moderate Intellectual Disability, SID = Severe Intellectual Disability, Aut = Autism, Mot Dif = Motor Difficulty and FD = Facial Dysmorphisms, SLD = speech and/or language delay or impairment, IUGR = Intrauterine growth restriction, ADHD = Attention-deficit/hyperactivity disorder, LDO = learning difficulty only, ASD = Autism spectrum disorder, F = Female, M = Male. \*3 V = Patients with 3 VOUS (CNV). Pv = Patients with pathogenic CNV. \*2Pvp = Patients with 2 pathogenic CNVs.Figure 2VOUS per chromosome.

Four of these VOUS (in cases \#180, \#223, \#384 and \#444) are discussed in greater detail, because they were considered potentially pathogenic, however with no compelling evidence at this point (Table [4](#Tab4){ref-type="table"}).Table 4CNVs Subclassified VOUS as potentially pathogenic VOUS.CaseTypeMicroarray NomenclatureSize (Kbp)N° of GenesN° of Genes in OMIMImportant GenesPhenotypeGender/Notes\#180Delarr\[hg19\] 16p13.3(6,243,228-6,835,898)x159311RBFOX1DD, HypothyroidismM/−\#223Duparr\[hg19\] 15q24.1(72,838,805-73,581,757)x374384BBS4Short stature, IUGR, DD, MID, FD, dolichocephaly, high-arched palate, microtia, breast hypertelorism and constipationM/\*3V\#223Duparr\[hg19\] 3p26.3(255,645-1,510,822)x31.25522CTN6, CHL1Short stature, IUGR, DD, MID, FD, dolichocephaly, high-arched palate, microtia, breast hypertelorism and constipationM/\*3V\#223Duparr\[hg19\] 6q25.3(156,488,875-158,534,725)x32.04594SNX9, ARID1BShort stature, IUGR, DD, MID, FD, dolichocephaly, high-arched palate, microtia, breast hypertelorism and constipationM/\*3V\#384Delarr\[hg19\] 16p13.3(7,108,169-7,225,285)x111711RBFOX1Mot Dif, Chronic Encephalopathy and spastic quadriparesisM/−\#444Delarr\[hg19\] 16p13.3(6,644,079-6,675,606)x13111RBFOX1DD and ASDM/−Variants of unknown significance with potential pathogenicity, found in the cohort, with the number of genes present in the region, listing the most relevant genes and phenotypes for each individual. Dup = Duplication, Del = Deletion, IUGR = Intrauterine growth restriction, DD = Developmental Delay, MID = Mild Intellectual Disability, FD = Facial Dysmorphisms, Mot Dif = Motor Difficulty, ASD = Autism spectrum disorder, F = Female, M = Male. \*3 V = Patients with 3 VOUS (CNV).

All other CNVs were interpreted as benign or as common genetic polymorphisms. In 70% of the cases, they were the only findings present in the genome of a patient, and thus considered a negative result for clinically relevant CNVs.

Figure [3](#Fig3){ref-type="fig"} Patients grouped according to the most relevant CNV found in their genomes.Figure 3Classification of cases per most relevant CNV found.

Phenotypic characterization {#Sec3}
---------------------------

Of the 420 cases, three were not included in the phenotypic characterization because it was not possible to obtain clinical data. The features registered in our cohort are listed in Table [5](#Tab5){ref-type="table"}. Most patients, besides the main reasons of referral (DD, ID, ASD) had additional characteristics, including dysmorphologies, psychiatric or behavioral issues, or variations in height or body weight, whose relation to the main problem often is unclear. Many have syndromic features, as can be concluded by the high presence of congenital abnormalities and atypical facial appearance. As expected, 80% of the individuals of the studied cohort had DD/ID (the main reasons for referral). DD and ID are cited here together because ID is only diagnosed above 5 years of age, however it is a known fact that most individuals with DD in early infancy will later be diagnosed with ID. Of the patients in our study 67% had DD at the time of the study or at an earlier age, with 41% considered intellectually disabled. Facial dysmorphisms (most of them minor) were reported for 53% and ASD for 32%. Other phenotypes were in lower frequencies. Univariate analysis (chi-square or Fisher's test when more appropriate) indicated predictive phenotypes for a higher diagnostic result (a higher chance to have a pathogenic CNV) in our cohort with ND: dysmorphic facial features (*p*-value = \<0.0001, OR = 0.32), obesity (*p*-value = 0.006, OR = 0.20), short stature (*p*-value = 0.032, OR = 0.44), genitourinary anomalies (*p*-value = 0.032, OR = 0.63) and ASD (*p*-value = 0.039, OR = 1.94) (Fig. [4](#Fig4){ref-type="fig"}). There was no significant higher diagnostic result by CMA for the other phenotypes.Table 5The clinical characteristics recorded for patients with negative and pathogenic CMA results.Signs/SymptomsIn the cohort (N = 417)Negative (N = 295)^\#^Pathogenic (N = 75)^\#^*p*-valueOdds ratio**CHARACTERISTICS**Obesity4% (16/417)2% (6)9% (7)0.006^\*f^0.20Low weight7.5% (31/417)6% (18)13% (10)0.0610.42Abnormal growth3% (12/417)3% (8)5% (4)0.277^f^0.49Short stature11% (45/417)9% (27)19% (14)0.032^\*^0.44Slender build7% (30/417)6% (19)8% (6)0.8230.79Prenatal problems6% (25/417)------Positive family history18% (75/417)16% (48)19% (14)0.0740.84of Intellectual disability or developmental delay13% (54/417)---------of Congenital anomalies6.5% (27/417)---------of Psychiatric disorder7% (30/417)---------**NEURODEVELOPMENT**---------Developmental delay67% (281/417)64% (188)76% (57)0.0610.55Motor development delay11% (47/417)9% (28)12% (9)0.6660.76Deafness or hearing loss2% (10/417)2% (6)4% (3)0.394^f^0.49Speech and language delay and/or dyslalia33% (137/417)35% (102)36% (27)0.9240.93Difficulty of learning10% (44/417)10% (31)8% (6)0.6671.34Intellectual disability41% (171/417)39% (115)47% (35)0.2800.73Mild6% (26/417)------Moderate2% (10/417)------Severe4% (18/417)------Not Specified28% (117/417)------Intellectual disability and/or developmental delay80% (334/417)77% (227)76% (57)0,9831.05**BEHAVIORAL**------Behavioral changes (Obsessive-compulsive disorder, attention deficit hyperactivity disorder, self and hetero-aggression, behavior disorder, psychosis)19% (78/417)18% (53)20% (15)0.8110.876Autism Spectrum Disorder32% (134/417)35% (102)21% (16)0.039\*1.94Syndromic Autism11% (44/417)------Asperger Syndrome2% (7/417)------Non-Syndromic Autism20% (83/417)------**CONGENITAL MALFORMATION(S) AND/OR DYSMORPHISM(S)**58.5% (244/417)------**FACIAL MALFORMATIONS/DYSMORPHISMS**53% (222/417)47% (139)73% (55)\<0,0001\*0,32Long face2% (10/417)------Wide face0% (1/417)------Narrow face1% (4/417)------Triangular face1% (3/417)------Asymetrical face2% (9/417)------Cleft palate3% (12/417)------Micrognathia3% (13/417)------Mouth/Lips (unusual)5% (21/417)------Microcephaly (Craniosynostosis included)8% (33/417)------Macrocephaly3% (13/417)------Ears (dysmorphic)11% (46/417)------Eyes (unusual)16% (68/417)------Forehead (unusual)2% (7/417)------Eyebrows (unusual)2% (7/417)------Nose (unusual)5% (25/417)------Hair (unusual)2% (10/417)------Not Specified18% (76/417)------**OTHER CONGENITAL MALFORMATIONS**------Musculoskeletal (scoliosis, diaphragmatic hernia, vertebral anomaly)19% (78/417)8% (24)4% (3)0.3262.12Upper limb anomalies8% (33/417)7% (22)8% (6)10.92Lower limb anomalies7% (30/417)9% (27)13% (10)0.3880.65Heart anomalies and malformations9% (36/417)8% (23)12% (9)0.3540.62Gastrointestinal anomalies and malformations8% (34/417)6% (18)9% (7)0.4600.63Genitourinary anomalies and malformations6% (25/417)5% (16)13% (10)0.032^\*^0.37**NEUROLOGIC ABNORMALITY**37% (155/417)30% (88)35% (26)0.5020.80Epilepsy and/or seizures15% (61/417)------Ataxia2% (9/417)------Hypotonia8% (32/417)------Abnormal brain structure13% (53/417)------Endocrinological abnormalities5% (23/417)4% (12)7% (5)0.354^f^0.59**CUTANEOUS ABNORMALITIES**(hyper and hypopigmentation, hemangioma, freckles, café-au-lait spots and others)4% (19/417)3% (10)7% (5)0.198^f^0.49**HEMATOLOGIC ABNORMALITIES**3% (14/417)3% (9)3% (2)1^f^1.14^\#^Patients with VOUS as most relevant CNV found were excluded from the correlation, because they represent inconclusive diagnosis. **\***Significant statistical correlation found between pathogenic CNV and phenotype. ^f^In phenotypes with n \< 20, Fisher's test was more appropriate.Figure 4Odds ratios of pathogenic CNVs in cohort study patients. Odds ratios shown in log2 scale. Odds ratios with a p-value \< 0.05, two tailed were displayed in red, while others were shown in black. \*\*p-value \< 0.001. CM: Congenital malformations, ID: Intellectual disability; DD: Developmental delay and ASD: Autism spectrum disorder.

Table [5](#Tab5){ref-type="table"} summarizes the clinical features recorded for patients with negative and positive CMA results with the percentage (and number) of patients presenting them. Most patients have more than one relevant phenotype.

Classical karyotyping and CMA {#Sec4}
-----------------------------

Seventeen patients informed previous abnormal karyotyping results (Table [6](#Tab6){ref-type="table"}), three of which are not very understandable or with a question mark (\#282, \#412 and \#430). For 12 cases, CMA specified the sequences involved, often with unexpected findings, hinting to the mechanism of occurrence of the anomaly and explaining phenotypes that the karyotype by itself suggested otherwise. In case \#196, for instance, CMA identified a deletion in the short arm of chromosome 5, whereas the chromosomal analysis of the patient (46, XX, 5p+) indicated additional DNA in chromosome 5. CMA revealed also that the additional DNA in chromosome 5 originated from a partial duplication of the long arm of chromosome 18. For another case, \#263 (47, XY +mar), a large deletion was found instead of a gain. Regarding the five cases where the cytogenetic analysis was abnormal and no pathogenic CNV was identified, in one (\#138) a VOUS with no apparent relation to the chromosome analysis result was found whereas the other four had a normal CMA result, including the three cases whose informed karyotype was followed by a question mark, indicating that the chromosomal analysis was not conclusive (Table [6](#Tab6){ref-type="table"}).Table 6Cases with previous abnormal chromosomal results.caseKaryotypeCMA arr\[hg19\]Size (Kbp)InterpretationNotes\#4446, XX, del(22)(q13)22q13.2q13.33(43,600,479-51,197,766)x17.597Phelan-McDermid SyndromeAs expected, CMA showed a deletion in chromosome 22, where the sequence involved was clarified.\#56XY,46, del(8)(p21-p11)8p21.1p11.21(28,393,484-41,026,001)x112.6328p11.2 deletion syndromeAs expected, CMA showed a deletion in chromosome 8, where the sequence involved was clarified.\#11646, XY, add(22q)Xq26.3q28(135,224,845-155,233,098)x220.008Region includes Xq26.3, Xq27.3-q28 and Xq28 duplication syndromesCMA showed that the DNA added to chromosome 12 derived from the terminal part of chromosome Xq.\#12746, XX, add(18)(q23)10q25.1q26.3(108,553,165-135,427,143)x326.873Distal trisomy 10q syndrome andDistal 18q deletion syndromeCMA showed that the additional DNA in chromosome 18 is derived from chromosome 10q, probably as result of an unbalanced t(18,10), causing also deletion of the terminal part of 18q. It is possible that one of the parents is an equilibrated carrier of the translocation.18q22.3q23(69,055,745-78,014,123)x18.958\#19646, XX,5p+18q21.2q22.1(49,094,563-66,586,144)x317.492Distal trisomy 18q*Cri du Chat* syndromeCMA showed that the additional DNA in chromosome 5 is derived from chromosome 18q, probably as result of an unbalanced t(5,18), causing also a large deletion of the terminal part of 5p. It is possible that one of the parents is an equilibrated carrier of the translocation.18q22.1q23(66,593,317-78,014,123)x311.4215p15.33p15.2(113,576-12,747,875)x112.634\#21946, XX, add(8)(p23.1)8p23.1p11.22(11,935,023-39,246,760)x327.3118p inverted duplication/deletion \[invdupdel(8p)\] syndromeCMA showed that the additional DNA in chromosome 8 is indeed from the same chromosome and also a deletion in 8p occurred, characterizing the 8p inverted duplication/deletion syndrome.8p11.22p11.21(39,388,765-42,335,424)x36.7828p23.3p23.1(158,048-6,940,661)x13.882\#26347, XY +mar9p24.2p22.2(4,339,192-18,272,756)x113.9349p deletion syndromeUnexpectedly the CMA revealed a deletion in chromosome 9, instead of additional DNA for the marker chromosome. Possibly the marker chromosome is satellite DNA.\#30546, XY, add(X)(p22)Xq27.3q28(142,412,280-155,233,098)x212.821Region includes Xq27.3-q28 and Xq28 duplication syndromesA duplication was found, as expected, showing that it refers to the terminal region of the X chromosome itself.\#33946, XX, Inv (12)(p13q24.1)12p13.2p13.1(10,922,516-12,937,320)x12.015A pericentromeric inversion with a deletion in chromosome 12CMA showed that the inversion caused a deletion in 12p13.\#39246, XY, r(21)(p21q22.3)\[?\]/46, XY, idic(21)(p13)\[?\]21q11.2q22.3(15,006,457-44,968,648)x329.962Trisomy of chromosome 21 with a loss of the distal part of 21q22.3CMA showed the trisomy of chromosome 21q, 21(11.2q22.3), revealing that the ring chromosome probably is iso21(11.2q22.3), with a deletion in the distal part of 21(22.3q).21q22.3(44,974,017-45,685,800)x371121q22.3(45,685,800-48,097,372)x12.411\#42247, XY +mar18p11.32p11.21(136,227-15,099,116)x414.963Tetrasomy 18pCMA revealed that the marker chromosome is an isochromosome 18p.\#40746, XX, add(21)(q22.3)3q26.1q29(166,855,496-197,851,444)x330.9963q26.1-q29 duplication syndromeCMA showed that the additional DNA on chromosome 21 derived from chromosome 3q.\#13846, XY, del(Yp)\[30\]VOUS6p21.2(37,609,169-37,868,513)x3259A small duplication in chromosome 6, considered a VOUS was found.New karyotyping to clarify previous test would be advisable.\#17546, XY, t(4; 7) (q31; p14)Normal CMA result---Probably a balanced translocationOne translocation break point possibly disrupted a gene that causes the phenotype. Break-point mapping and sequencing would be advisable.\#28246, XY, der(10p)? translocation?Normal CMA result---Possibly a balanced translocation. There was a question mark.New karyotyping to clarify previous test would be advisable.\#41246, XY, add(13)?Normal CMA result---There was a question mark. Possibly a new karyotyping could give clearer results.New karyotyping to clarify previous test would be advisable.\#43046, XX, add(13) PSK?Normal CMA result---There was a question mark. Possibly a new karyotyping could give clearer results.New karyotyping to clarify previous test would be advisable.

Discussion {#Sec5}
==========

In the present study, a total of 96 pathogenic CNVs were detected in CMA results of 75 patients with ND in the state of Santa Catarina, a diagnostic yield of 18%, within the range of 15--20% diagnostic rate cited in literature for patients with ND in other cohorts^[@CR5],[@CR9],[@CR11]--[@CR17]^. It is important to highlight that the 75 patients with pathogenic CNVs, included 12 patients of the 17 with previous abnormal karyotype result, for whom the CMA test was requested in order to identify the DNA sequences involved. Excluding the 17 cases with known abnormal karyotype results in a diagnostic rate of 15.63%, and when considering only the 122 patients that underwent previous karyotyping and had normal results, the diagnostic rate was not different, 15.57%. However, the diagnostic yield was considered 18% because CMA was essential to uncover the sequences altered in the abnormal karyotype results, and thus was diagnostic, unveiling unexpected findings, like deletions in chromosomes whose karyotype showed additions or deletion when karyotype had suggested addition. These are exemplified by case \#127 \[46, XX, add(18) (q23)\] CMA identified a distal trisomy of 10q with simultaneous distal 18q deletion and for \#196 (46, XX, 5p+) CMA revealed a distal trisomy 18q together with a distal deletion in 5p. For case \#263 (47, XY +mar), a new chromosomal analysis would be desired, because instead of additional DNA, a large pathogenic deletion in chromosome 9 was found. The CMA results of the 17 cases for whom a previous abnormal chromosomal analysis was reported, are depicted in Table [6](#Tab6){ref-type="table"}, case by case, together with comments about the findings.

Conversely, our results also point to the usefulness of traditional karyotyping to complement the CMA results, allowing an insight into the mechanisms that gave rise to the genetic abnormality, which is relevant for genetic counselling. For instance, from the 15 cases that had more than one rare CNV (pathogenic CNV or VOUS) and no previous abnormal karyotyping, eight involved the terminal region of chromosomes, some of them quite large, combining terminal deletions with terminal duplications, suggesting that they might be derivative chromosomes that arose form a translocation. This can be seen in case \#61 (Table [1](#Tab1){ref-type="table"}) with a distal trisomy of chromosome 8q and a simultaneous deletion in the end of the long arm of chromosome 13; \#151, with a terminal del18p and a terminal trisomy 7p; \#188, with a terminal del21q and a terminal trisomy 19p; \#251, with a terminal del20q and a terminal trisomy 19p; \#270, with a terminal del18q and a terminal trisomy 3q; \#332, with a terminal del7q and a terminal trisomy 3q; \#372, with a terminal del8p and a terminal trisomy 4p, and case \#407, with a terminal del21q and a terminal trisomy. This derivative chromosome could have been originated during meiosis, during the first mitotic divisions of the zygote or possibly were inherited from a healthy parent that carries the translocation in an equilibrated state. In latter case there is a risk of recurrence for the same or possibly the complementary derivative in another child. Three cases had 2 or 3 CNVs within the same chromosome: case \#33, where the microarray result points to a circular chromosome 18, since both ends are deleted; case \#331, with two deletions and one duplication, suggesting a del/dup inversion, and case \#47, that had two small deletions on the tip of the p arm, surrounding the SHOX gene, indicating a possible del/del inversion including SHOX. Other cases had a combination of interstitial or terminal and interstitial CNVs in two or more chromosomes, pointing to more complex mechanisms.

In 2010, the American College of Medical Genetics recommended CMA as first-tier test for the population of individuals with DD, ID, ASD and multiple congenital anomalies. We agree with that. However, about the often-made question if CMA is a substitute for the classical chromosome analysis or even if CMA is causing karyotyping to be obsolete, we consider that a correct diagnosis requires the combination of CMA and chromosome analysis as stated by others^[@CR21]^, which observed structural rearrangements in addition to simple deletions or duplications under the microscope in 85 (18%) of 469 cases with an abnormal CMA result. Likewise, chromosome analysis of the parents of individuals with clearly pathogenic terminal deletions/duplications or large CNVs (regardless if terminal or interstitial) should be a follow-up rule, because this knowledge is essential for genetic counselling. For instance, the karyotype of a father of two affected siblings, a girl (\#149) with a large deletion in chromosome 5 \[5p14.3--p15.31 (6,801,589--18,992,827)\] and her brother, \#445, with a duplication of the exact same region, revealed complex translocations involving at least four chromosomes, 46, XY, t (1; 2) (q44; \~p23-pter); t(5; 7) (p14.3--p15.31; p22) (Table [1](#Tab1){ref-type="table"}). The genome of this father survived catastrophic events with no obvious clinical consequence for him which, however, left rearrangements (not detectable by MCA) whose deleterious reflexes did affect deeply the development of his two children -- in two distinct (or opposite) molecular ways midst an even larger array of possibilities.

Among 17 abnormal karyotypes we had at least one equilibrated translocation, case \#175 \[46, XY, t(4; 7) (q31; p14)\], whose CMA result showed no CNV. This is an interesting case to study because it is unlikely that this translocation has no pathogenic relevance. Possibly the translocation disrupts or interferes with the regulation of the causal gene, which could be identified by breakpoint mapping/sequencing.

The pathogenic CNVs found in this study and the reported phenotypes of the respective patients are detailed in Table [1](#Tab1){ref-type="table"}. It is known that most pathogenic CNVs occur "*de novo*" because of an error during meiotic recombination, an early illegitimate mitotic recombination, or the mutagenic repair of DNA double-strand breaks during the first divisions of the embryonic cells^[@CR22]^. They can also be consequence of a balanced chromosomal translocation in the genome of one of the parents, therefore classical karyotype test for parents of individuals with large pathogenic CNVs is advisable, since balanced translocations cannot be identified by CMA and there is a high risk of recurrence^[@CR23]^.

We tried to draw comparisons between pathogenic CNVs detected between various studies, which is a challenge, since each study used distinct CMA platforms with probes of varying sizes, densities and characteristics. To allow a comparison, we made a circle plots with the pathogenic CNVs detected in our study together with the pathogenic CNVs detected in cohorts of North America^[@CR24],[@CR25]^ and Europe^[@CR13]--[@CR15],[@CR26],[@CR27]^ using studies that made the data sufficiently available for such analysis (Fig. [5](#Fig5){ref-type="fig"}).Figure 5The circle plot compares pathogenic CNVs found in: (first, the outhermost double track) our study of a cohort of 420 individuals with neurodevelopmental disorders (ND), derived from a complex population in the south of Brazil, mostly composed by the Portuguese conquerors, German and Italian immigrants, besides descendants of slaves and of Amerindians; (second double track from the border) studies of 1.245 individuals from five affected European cohorts; (third double track) studies of 15.901 individuals from two affected North American cohorts; (fourth, innermost double track) the pathogenic CNVs detected exclusively in our study, when compared to the other studies in the plot.

Among the studies of the circle plot, the following pathogenic CNVs were detected exclusively in our sample: arr\[hg19\] 1p36.33p36.32(1,073,574--2,458,606)x1, arr\[hg19\] 2q31.1-q31.2(174,065,715--190,659,870)x1, arr\[hg19\] 4p16.3p16.1(68,345--9,509,606)x3, arr\[hg19\] 4p16.3(68,345--964,416)x1, arr\[hg19\] 7p22.3p21.3(43,376--9,454,786)x3, arr\[hg19\] 7q31.32q33(122,736,512--136,162,906)x3, arr\[hg19\] 8p21.1p11.21(28,393,484-41,026,001)x1, arr\[hg19\] 8p11.22p11.21(39,388,765--42,335,424)x3, arr\[hg19\] 12p13.2p13.1(10,922,516--12,937,320)x1, arr\[hg19\] 13q33.1q34(104,782,510--112,352,804)x1, arr\[hg19\] 16p13.3(85,880--2,145,951)x1, arr\[hg19\] 18p11.32p11.31(136,226--4,409,550)x1, arr\[hg19\] 19p13.3(260,911--1,434,508)x3, arr\[hg19\] 21q11.2q22.3(15,006,457--44,968,648)x3, arr\[hg19\] 21q22.12q22.2(35,834,713--39,831,660)x1, arr\[hg19\] 22q12.3q13.1(35,888,588--38,692,765)x4, arr\[hg19\] Xp22.3q28(1--247,249,719)x3, arr\[hg19\] Xp22.33(372,029--578,764)x1, arr\[hg19\] Xp22.33(679,520--950,907)x1, arr\[hg19\] Xq26.3q28(135,224,845--155,233,098)x2, arr\[hg19\] Xq27.3q28(142,412,280--155,233,098)x2, arr\[hg19\] Xq27.3q28(146,425,635--151,604,987)x2 and arr\[hg19\] Xq27.3q28(146,418,810--151,604,987)x2.

The interpretation of CNVs is not an absolute science and caution must be used in the report of the results. Palmer *et al*. (2013) already presented data on how the interpretation of CNVs detected by CMA had a significant change over time, with an increase in CNVs classified as pathogenic as new studies and case descriptions are reported. That is why it is important to register the CNVs interpreted as VOUS when no pathogenic CNV is found. In our study we found VOUS (as the most relevant CNV) in 12% (49/420) of the patients in the cohort (Table [2](#Tab2){ref-type="table"}). Although we believe that most of them will have no clinical impact, some of the CNVs in this subgroup possibly will be classified as pathogenic in the future, as more data accumulates. Bellow we highlight four cases where we considered the VOUS potentially pathogenic:

Case \#223 = Refers to a boy that was ten years old when he was referred for CMA. He presented short stature, intrauterine growth restriction, DD, mild ID, a narrow face, dolichocephaly, high-arched palate, microtia (small ears), nipple hypertelorism and constipation. His MCA revealed no pathogenic CNV, however three duplication VOUS (Table [4](#Tab4){ref-type="table"}), of which two were considered potentially pathogenic: arr\[hg19\] 3p26.3(255,645--1,510,822)x3 and arr\[hg19\] 6q25.3(156,488,875--158,534,725)x3, whose inheritance is unclear. The region arr\[hg19\] 3p26.3(255,645--1,510,822)x3 duplicates the entire sequence of the contactin 6 gene (CNTN6), LINC01266, a long intergenic ncRNA, and the final of the CHL1 gene (cell adhesion molecule L1 like). CHL1 has been proposed as a candidate gene for intellectual disability of the 3p deletion syndrome^[@CR28],[@CR29]^, and one partial duplication of a similar portion of the CHL1 gene as in case \#223 was described, including also the complete CDS of LINC01266, and a small portion of the CNTN6 gene^[@CR30]^. It is not clear if the partial duplication of CHL1 in was originated by some rearrangement that could have disrupted one of the complete copies of the gene. Contactin 6, encoded by CNTN6 is a neural cell adhesion molecule that has been proposed as one of the critical genes of the 3p deletion syndrome^[@CR31]^ and deletions or duplications of CNTN6 was suggested to be associated to a wide spectrum of neurodevelopmental disorders^[@CR32]^. The 6q25.3(156,488,875--158,534,725) genomic region contains the complete sequences of the genes ARID1B (AT-rich interaction domain 1B), TMEM242 (Transmembrane Protein 242), ZDHHC14 (Zinc Finger DHHC-Type Containing 14), SNX9 (Sorting Nexin 9), SYNJ2 (Synaptojanin 2), the beginning of the SERAC (Serine Active Site Containing 1) gene, and the microRNA genes MIR4466 and MIR3692. No complete duplication of any of these genes was found on the DGV. Of those, SYNJ2 is majoritarily expressed in the brain^[@CR33]^ and is a member of the synaptojanin family, which are key players in the synaptic vesicle recovery at the synapse; TMEM242 is a potential multi-pass membrane protein of unknown function^[@CR34]^, that is expressed in most tissues^[@CR33]^**)**, however, with highest expression in the brain; ZDHHC14 is a probable palmitoyltransferase^[@CR34]^ whose expression is highest in the brain and utherus^[@CR33]^; SNX9 could involved in several stages of intracellular trafficking and is espressed is most tissues, with very low brain expression^[@CR33]^ and ARID1B is a component of the SWI/SNF chromatin remodeling complex and its haploinssuficiency is one of the most frequent causes of ID, both, syndromic (Coffin-Siris syndrome) and non-syndromic^[@CR35]--[@CR38]^. Coffin-Siris syndrome is characterized by, feeding difficulties in infancy, delayed motor skills, severe speech impairment, mild to severe ID, coarse facial features, hirsutism and its hallmark is the hypoplasia or absence of the 5th distal phalanx of the finger and/or toes. Up to now, only intragenic duplications that probably disrupt gene function were described, however no complete duplication of the gene ARID1B has been described. Duplications comprising the region of chromossome 6 that is duplicated in case \#223 are much larger, with the exception of one registered in Decipher, for patient: 287902 with microcephaly and ID, that has a "de novo" duplication of about the same size as the one in our case. Other three duplications including only complete ARID1B alone or with one more gene are also in Decipher, all being the only, or the only non-inherited CNV, found.

Cases \#180, \#384 and \#444 refer to three boys, 4, 2, and 5 years old, respectively, at the date of referral for CMA, because of DD (\# 180), motor delay, chronic encephalopathy and spastic quadriparesis (\# 384), and DD and ASD (\# 444), all of them with a different intragenic deletion in the gene RBFOX1. The RBFOX1 gene (OMIM \* 605104), also known as Ataxin-2-binding protein 1 (A2BP1) or FOX1, is one of the largest genes in the human genome and encodes a neuronal RNA binding protein that is highly conserved evolutionarily. It has a very complex transcription unit that generates transcripts from multiple promoters, and presents alternative termination sites. The inclusion of its multiple internal exons is highly regulated, yielding various nuclear and cytoplasmic protein isoforms^[@CR39]^. In the nucleus, RBFOX1 protein isoforms act as RNA processing factors, while in the cytoplasm they act as proteins that regulate the stability and translation of RNAs involved in cortical development and autism^[@CR40],[@CR41]^.

Changes in RBFOX1 have been related to several neurodevelopmental syndromes, including ID, epilepsy, and ASD^[@CR42]--[@CR44]^, with important roles in neuronal migration and synapse network formation during corticogenesis^[@CR45]^. Specifically, intragenic deletions have been related to neuropsychiatric and neurodevelopmental disorders^[@CR42],[@CR46],[@CR47]^.

The case \#180 showed a microdeletion 593 Kbp (arr\[hg19\] 16p13.3(6,243,228--6,835,898)x1), eliminating exon 1 from transcript variant 6 (isoform 4 NM_001142334.1) and exons 2 and 3 from transcripts variants 4, 5 and 7 (respectively, isoform 4 NM_018723.3, isoform 5 NM_001142333.1 and isoform 6 NM_001308117.1).of the gene RBFOX1 which in the reference sequence are non-coding exons of the 5 ' region. Besides possibly affecting the transcription of the main isoforms, this microdeletion also affects the promoter of several isoforms of RBFOX1, whose transcription begins after exon two.

Case \#384 presented one microdeletion 117 kbp in 16p13.3 (arr\[hg19\] (7,108,169--7,225,285)x1), involving an intronic region between exon 4 and 5 from transcripts variants 4, 5 and 7 (respectively, isoform 4 NM_018723.3, isoform 5 NM_001142333.1 and isoform 6 NM_001308117.1) and between exon 2 and 3 from from transcript variant 6 (isoform 4 NM_001142334.1) of the RBFOX1 gene, and case \#444 had microdeletion of 31 kbp (arr\[hg19\] 16p13.3(6,644,079--6,675,606)x1) in intron 2 from transcripts variants 4, 5 and 7 (respectively, isoform 4 NM_018723.3, isoform 5 NM_001142333.1 and isoform 6 NM_001308117.1) of the RBFOX1 gene, affecting various isoforms and possibly affecting the isoform promoter region that initiates from transcript variant 6 (isoform 4 NM_001142334.1) after exon 3 of the reference sequence.

It is topic of ongoing discussion of how to communicate the CNVs findings in the reports, where the communication of VOUS is particularly challenging. In clinical practice, it is a confounding factor to have a CNV about which no one can say something for sure. The limitations of the test and, more shockingly, of the current understanding of the results are difficult for the clinician to explain and even more difficult for the patient/guardians to understand. They often cannot settle for the idea that they underwent such an expensive test and the doctors cannot say anything useful or definitive with the results. Even though adequate pre-testing explanation is provided to patients or their guardians, and they sign a consent form which also lists the limitations of the test, for many persons the real understanding of what that means only sinks in after receiving an ambiguous CMA result. It is much easier to explain a negative result that, if not answering the question of why the neurodevelopment was disturbed, at least answers that it is not caused by a genomic imbalance produced by an excess or a deletion of genetic material. A VOUS tends to represent a point of frustration for all involved. The American College of Medical Genetics allows to communicate the likelihood that a VOUS is pathogenic or benign, when well founded in the report and the uncertainty of such classification is clearly communicated. In addition, they also recommend that the report includes guidelines for the continuous monitoring of medical literature, since new knowledge can clarify the CNV's real clinical impact.

One strategy in the interpretation of a VOUS is to investigate if it occurred "de novo" or has been inherited from one of the parents. Inherited CNVs are more likely benign, whereas "de novo" variants found in ND patients have a greater chance to be causal. However, the incomplete penetrance or variable expression of a clinical phenotype can explain the presence of a pathogenic CNV in an unaffected (or sub-clinically affected) parent. As well as a "de novo" event is indicative, but not necessarily the cause of the disorder.

In regard to their size, the pathogenic CNVs were typically very large (Fig. [6A](#Fig6){ref-type="fig"}), with a mean size of 7,770 kbp (median: 5,179 kbp), and contained multiple genes when compared with benign CNVs (mean: 483 kbp, median: 285 kbp, Fig. [6A,B](#Fig6){ref-type="fig"}) and VOUS (mean: 666 kbp, median: 382 kbp), as shown in Fig. [6A,C](#Fig6){ref-type="fig"}, in agreement to findings by others^[@CR25],[@CR48],[@CR49]^. The variation inside each class is very large and some pathogenic CNVs are quite small whereas some benign CNVs can be very large when they are situated in gene-poor regions, like those close to centromeres. It is to expect that a VOUS is not typically very large because the more genes a CNV contains the higher chance of including known dosage-sensitive genes, regulatory regions or, in case of a deletion, to expose a recessive mutation which may be present in the remaining copy of the gene.Figure 6(**A**) CNV type by size variation. (**B**) Benign CNV size variation on a larger scale. (**C**) VOUS size variation on a larger scale.

Based on the clinical data, obtained from the medical records, the most frequent phenotypes reported are also the main reasons of referral: DD, ID, congenital anomalies and/or dysmorphia, and ASD (Table [4](#Tab4){ref-type="table"}). The same phenotypes are predominant in other CMA studies for the investigation of neurodevelopmental disorders^[@CR4],[@CR5],[@CR9],[@CR11],[@CR14]--[@CR18]^.

For instance, congenital anomalies, along with facial dysmorphisms, were reported in more than 58% of our cohort (Table [4](#Tab4){ref-type="table"}). This frequency similar if the findings of 50% in a cohort of 78 affected with ND in the study of Qiao *et al*.^[@CR50]^ and the 55% reported by Roselló *et al*.^[@CR5]^ in their study with 246 patients with DD and ID, and probably represents a selection bias by the MDs for the referral for testing. Nevertheless, there was no statistical difference of diagnostic rate for patients with neurodevelopmental disorders without an obvious congenital anomaly or dysmorphia (data not shown).

Univariate analysis showed a significant association for the presence of pathogenic CNVs with dysmorphic facial features (*p*-value = \< 0.0001, OR = 0.32) and ASD (*p*-value = 0.039). Congenital anomalies only showed a higher association with pathogenic CNVs in this cohort when broken down into more specific affected systems, where genitourinary anomalies had a higher correlation with the finding of a pathogenic CNV (*p*-value = 0.032). Furthermore, two secondary phenotypes, obesity (*p*-value = 0.006) and short stature (*p*-value = 0.032), were shown to be phenotypes associated to higher findings of pathogenic CNVs in patients with ND. However, this are incipient results, and should be avoided to be used for testing decisions. A clinical and standardized reassessment in all cases and a larger sample would be crucial to confirm this.

As already discussed by Quintela *et al*.^[@CR26]^ the interpretation of genomic variations such as CNVs is an arduous task, especially in the challenging VOUS, when the genotype is suggestive of a genomic disorder characterized by incomplete penetrance and/or variable expressivity.

Regarding the negative diagnoses of the CMA (without CNVs or with only benign CNVs) in high resolution SNP CMA platforms like the ones used in this study, the homozygous regions can also be studied. Those results with very large LCSHs (long contiguous stretches of homozygosity) indicating possible uniparental disomy (UPD) or consanguinity should be reported to the accompanying MD for follow-up investigation of eventual imprinting syndromes or autosomal recessive mutations, through methylation or exome analysis. The relevance of LCSHs, which can be identified by most modern CMA platforms, is discussed elsewhere^[@CR51]^.

Conclusions {#Sec6}
===========

The diagnostic rate for CMA in this study was 18% and is within the literature (15--20%). CMA is an essential tool to decipher the sequences involved in structural karyotype abnormalities detected by classical chromosome analysis, as well as patients with abnormal CMA results should have their chromosomes analyzed - which can lead to unexpected surprises. For a correct diagnosis CMA and chromosome analysis should be used complementary. Parental chromosome analysis is essential for genetic counselling, particularly when the patient has terminal deletion/duplication or large CNVs. The main reasons for referral for CMA testing were DD/ID, dysmorphic facial features and ASD. Dysmorphic facial features and ASD (as main or secondary feature) and secondary phenotypes such as obesity, short stature, genitourinary anomalies are possible predictive phenotypes of a higher diagnostic answer by CMA.

Clinical interpretation of CNVs is still a challenge and depends in large part on information about their frequency in normal and affected populations, provided by cohort studies with significant samples.

Methods {#Sec7}
=======

Ethical aspects {#Sec8}
---------------

The project was submitted and approved by the Research Ethics Committee of the Hospital Infantil Joana de Gusmão, the children´s hospital of Florianópolis-SC, Brazil, under the Nr 2,339,104, and respects the guidelines and criteria of the resolution Nr 466/12 of the Brazilian National Health Council. Patients or their parent and/or legal guardian (in cases where patient was under legal age), signed the Informed Consent Form. In cases in which it was not possible to contact the patient for any justifiable reason (loss of contact information, mainly) the data was used and a Justification of Absence of Consent approved by Research Ethics Committee and signed by the research team, ensuring the commitment to maintain confidentiality and privacy of the patients whose data and/or information was collected in the records.

Sample {#Sec9}
------

The sample refers to the reading files of CMA and available clinical data from 420 patients from the south of Brazil, mostly children, with neurodevelopmental disorders. The CMAs were requested by medical geneticists and neurologists for diagnostic purposes, mainly from the Joana de Gusmão Children's Hospital, but also from the University Hospital Professor Polydoro Ernani de São Thiago and from private clinics in Florianópolis (State of Santa Catarina), throughout the years 2013 to 2016 and performed by the Laboratório Neurogene (Florianópolis, Santa Catarina, Brazil).

Collection of clinical data {#Sec10}
---------------------------

To correlate the phenotype to possible causal genes, the clinical description of the affected individuals was collected with their MDs through a questionnaire, seeking information about their clinical presentation, behavior, history of physical exams, as well as results of previous genetic and metabolic tests and prescription medication. No new appointments with the patients were made for this, and clinicians retrieved most data from their medical records.

Genomic analysis {#Sec11}
----------------

The platforms used were CYTOSCAN 750K (75%) and CYTOSCAN HD (25%) and the resulting files were analyzed using the CHROMOSOME ANALYSIS SUITE (ChAS) AFFYMETRIX software, based on the reference genome sequence of the University of California, Santa Cruz database (https-//genome.ucsc.edu/cgi-bin/hgGateway) using the human genome version of February 2009 (GRCh37/hg19). The filter criteria for CNVs were sizes \>100 Kbp for deletions and \>150 Kbp for duplications, both with at least 50 markers, according to ACMG recommendations^[@CR52]^.

CNVs interpretation and classification {#Sec12}
--------------------------------------

To interpret CNVs, regarding their function, dosage effects (known haploinsufficiency or overexpression studies) and effects of mutations, the UCSC Genome Browser with integrated databases was widely used, mainly ClinVar (NCBI), DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembles Resources), DGV (Database of Genomic Variants), OMIM (Online Mendelian Inheritance in Man), ISCA (International Standard Cytogenomic Array), dbGaP (Database of Genotypes and Phenotype), dbVAR (Database of Large Scale Genomic Variants), ECARUCA (European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations), PUBMED (Public Medline), ClinGen (Clinical Genome Resource), MGI (Mouse Genome Informatics Database, from The Jackson Laboratory) and the private database CAGdb (Cytogenomics Array Group CNV Database).

The variants were classified into three types according to clinical interpretation as benign, variants of uncertain significance (VOUS), or pathogenic variants (causal), and the result in each case was assigned based on the CNV(s) of greatest clinical relevance detected in the genome of the patients.

Variables like location, type and size of each CNV, the CNV classification, number of CNVs detected for each patients, age, gender, clinical descriptions (phenotypes), previous genetic testing results (karyotype, fragile X, etc.), and other relevant known clinical data, were compiled (with coded identification) into simple Excel sheet for data handling with the R software (version 3.4.2, the R FOUNDATION FOR STATISTICAL COMPUTING) in order to understand the phenotypic frequency, the diagnostic rate of the study, the average age and the gender distribution in the cohort, the frequency of genomic changes in each chromosome, and the relation of the phenotype (or groups of clinical phenotypes) to the type of CNV to find if there are any indications which allow to recognize the patients with higher chance of carrying a pathogenic CNV - most suitable for submission to the CMA as a first-line test in the unfortunate setting of financial shortage.

Ethics approval and consent to participate {#Sec13}
------------------------------------------

The project was submitted and approved by the Research Ethics Committee of the Hospital Infantil Joana de Gusmão, the children's hospital of Florianópolis-SC, Brazil, under the Nr 2,339,104, and respects the guidelines and criteria established by the resolution 466/12 of the Brazilian National Health Council. Patients or their caregivers signed the Informed Consent Form to participate in the study. In cases in which it was not possible to contact the patient for any justifiable reason (loss of contact information, mainly) the data was used and a Justification of Absence of Consent was signed by the research team, ensuring the commitment to maintain confidentiality and privacy of the patients whose data and/or information was collected in the records.
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